tiprankstipranks
NuCana Secures US Patent for Promising Cancer Drug
Company Announcements

NuCana Secures US Patent for Promising Cancer Drug

Nucana (NCNA) has released an update.

Pick the best stocks and maximize your portfolio:

NuCana plc has announced the US Patent and Trademark Office granted a new patent for NUC-7738, a novel anti-cancer agent showing promising results in a Phase 2 study for PD-1 inhibitor resistant melanoma. The patent significantly strengthens the drug’s intellectual property portfolio, which includes over 80 issued patents globally. This comes on the heels of positive data presented at the ESMO Congress, highlighting NUC-7738’s potential to improve outcomes for patients with metastatic melanoma.

For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNucana Reports Third Quarter Loss Amid R&D Investments
TheFlyNuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year
TipRanks Auto-Generated NewsdeskNuCana’s NUC-3373 Shows Promise in Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App